FAM215A and esophageal squamous cell carcinoma: These conclusions indicated that raltitrexed could enhance the promoted apoptosis effect of anlotinib on human ESCC cell lines KYSE-30 and TE-1 by affecting the expression of apoptosis-related proteins.